These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 17309914)
1. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Jain M; Venkatraman G; Batra SK Clin Cancer Res; 2007 Mar; 13(5):1374-82. PubMed ID: 17309914 [TBL] [Abstract][Full Text] [Related]
2. Engineered Antibodies as Cancer Radiotheranostics. Wei Z; Li B; Wen X; Jakobsson V; Liu P; Chen X; Zhang J Adv Sci (Weinh); 2024 Aug; 11(30):e2402361. PubMed ID: 38874523 [TBL] [Abstract][Full Text] [Related]
4. Aligning physics and physiology: Engineering antibodies for radionuclide delivery. Tsai WK; Wu AM J Labelled Comp Radiopharm; 2018 Jul; 61(9):693-714. PubMed ID: 29537104 [TBL] [Abstract][Full Text] [Related]
5. Advancing role of radiolabeled antibodies in the therapy of cancer. Goldenberg DM Cancer Immunol Immunother; 2003 May; 52(5):281-96. PubMed ID: 12700944 [TBL] [Abstract][Full Text] [Related]
6. Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection. Carter LM; Poty S; Sharma SK; Lewis JS J Labelled Comp Radiopharm; 2018 Jul; 61(9):611-635. PubMed ID: 29412489 [TBL] [Abstract][Full Text] [Related]
7. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Thurber GM; Schmidt MM; Wittrup KD Adv Drug Deliv Rev; 2008 Sep; 60(12):1421-34. PubMed ID: 18541331 [TBL] [Abstract][Full Text] [Related]
8. Emerging trends for radioimmunotherapy in solid tumors. Jain M; Gupta S; Kaur S; Ponnusamy MP; Batra SK Cancer Biother Radiopharm; 2013 Nov; 28(9):639-50. PubMed ID: 23844555 [TBL] [Abstract][Full Text] [Related]
9. Targeting neutrophil elastase is a promising direction for future cancer treatment. Jia W; Mao Y; Luo Q; Wu J; Guan Q Discov Oncol; 2024 May; 15(1):167. PubMed ID: 38750338 [TBL] [Abstract][Full Text] [Related]
10. Approaches to Reducing Normal Tissue Radiation from Radiolabeled Antibodies. Suzuki H; Kannaka K; Uehara T Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675468 [TBL] [Abstract][Full Text] [Related]
12. Direct In Vivo Comparison of Tolmachev V; Bodenko V; Oroujeni M; Deyev S; Konovalova E; Schulga A; Lindbo S; Hober S; Bragina O; Orlova A; Vorobyeva A Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499504 [TBL] [Abstract][Full Text] [Related]
13. Human Antibody Domains and Fragments Targeting Neutrophil Elastase as Candidate Therapeutics for Cancer and Inflammation-Related Diseases. Chu X; Sun Z; Baek DS; Li W; Mellors JW; Shapiro SD; Dimitrov DS Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681796 [TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target. Sabanathan D; Lund ME; Campbell DH; Walsh BJ; Gurney H Ther Adv Med Oncol; 2021; 13():17588359211022918. PubMed ID: 34646364 [TBL] [Abstract][Full Text] [Related]
15. Inverse electron demand Diels-Alder click chemistry for pretargeted PET imaging and radioimmunotherapy. Sarrett SM; Keinänen O; Dayts EJ; Dewaele-Le Roi G; Rodriguez C; Carnazza KE; Zeglis BM Nat Protoc; 2021 Jul; 16(7):3348-3381. PubMed ID: 34127865 [TBL] [Abstract][Full Text] [Related]
16. Perspectives on metals-based radioimmunotherapy (RIT): moving forward. White JM; Escorcia FE; Viola NT Theranostics; 2021; 11(13):6293-6314. PubMed ID: 33995659 [TBL] [Abstract][Full Text] [Related]
17. The Current Landscape of Antibody-based Therapies in Solid Malignancies. Shah A; Rauth S; Aithal A; Kaur S; Ganguly K; Orzechowski C; Varshney GC; Jain M; Batra SK Theranostics; 2021; 11(3):1493-1512. PubMed ID: 33391547 [TBL] [Abstract][Full Text] [Related]
18. Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment. Gierlich P; Mata AI; Donohoe C; Brito RMM; Senge MO; Gomes-da-Silva LC Molecules; 2020 Nov; 25(22):. PubMed ID: 33202648 [TBL] [Abstract][Full Text] [Related]